Evaluation of HER2 Expression in Prostate Cancer among Mexican Patients

Our study shows that expression of HER2 in prostate cancer in Mexican population is similar to that reported in other countries and that this biomarker could be used as a prognostic factor. As well, the overexpression of this protein might be used as a targeted therapy since there is evidence of the use of drugs such as fam-trastuzumab deruxtecan in different types of tumors that have a low expression of HER2, adding a new possible therapeutic weapon in a tumor with limited therapeutic options.